NCT00035893 arm group cbd60965ad801beed93237aa4e931f3f [clinicaltrials_resource:NCT00035893/arm-group/cbd60965ad801beed93237aa4e931f3f]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00035893 arm group cbd60965ad801beed93237aa4e931f3f [clinicaltrials_resource:NCT00035893/arm-group/cbd60965ad801beed93237aa4e931f3f]
Bio2RDF identifier
NCT00035893/arm-group/cbd60965ad801beed93237aa4e931f3f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... d60965ad801beed93237aa4e931f3f
description [clinicaltrials_vocabulary:description]
Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.
identifier
clinicaltrials_resource:NCT00035893/arm-group/cbd60965ad801beed93237aa4e931f3f
title
NCT00035893 arm group cbd60965ad801beed93237aa4e931f3f
@en
type
label
NCT00035893 arm group cbd60965 ...... 60965ad801beed93237aa4e931f3f]
@en